NCT07593547 Combination vs. Monotherapy for Stenotrophomonas Maltophilia Infections
| NCT ID | NCT07593547 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Instituto de Investigación Sanitaria Gregorio Marañón |
| Condition | Bloodstream Infection |
| Study Type | OBSERVATIONAL |
| Enrollment | 790 participants |
| Start Date | 2026-03-06 |
| Primary Completion | 2026-09-01 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 790 participants in total. It began in 2026-03-06 with a primary completion date of 2026-09-01.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The goal of this multicentre observational study is to analyse the treatment strategies and the outcomes for patients with S. maltophilia infections using target trial emulation methodology. The main question it aims to answer is: • Does combined therapy achieve better results than monotherapy in treating S. maltophilia infections? Researchers will compare groups receiving monotherapy and combined therapy to see if there are differences in all-cause 30-day mortality.
Eligibility Criteria
Inclusion Criteria: * Adult patients * S. maltophilia infections * Different episodes if a new infection ocurred \> 30 days since the index episode Exclusion Criteria: * isolates obtained from patients outside of hospital admission * microbiological or clinical colonization * hospitalizations shorter than 72 hours since the time zero * patients who died in the first 72 hours since the time zero or who were in imminent risk of death * polymicrobial infections * receipt of inappropriate therapy after the time of the emulated randomization, defined as the absence of in vitro active antimicrobials or the administration of active antimicrobials for less than 48 hours * absence of data outcomes
Contact & Investigator
Frequently Asked Questions
Who can join the NCT07593547 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Bloodstream Infection. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07593547 currently recruiting?
Yes, NCT07593547 is actively recruiting participants. Contact the research team at sofiadela.villa@salud.madrid.org for enrollment information.
Where is the NCT07593547 trial being conducted?
This trial is being conducted at Madrid, Spain.
Who is sponsoring the NCT07593547 clinical trial?
NCT07593547 is sponsored by Instituto de Investigación Sanitaria Gregorio Marañón. The trial plans to enroll 790 participants.